The US Food and Drug Administration has approved Merck & Co’s Lipfendra, known generically as enlicitide, to lower low-density lipoprotein cholesterol in patients whose levels remain elevated despite standard statin treatment, according to the company. Enlicitide is a macrocyclic peptide and the first oral inhibitor of PCSK9, providing a novel alternative to injected antibody therapies that have been available for cardiovascular disease management since 2015, according to Merck executive director head of biocatalysis David Thaisrivongs.
Manufacturing Challenges in Developing Oral PCSK9 Inhibitors
Designing enlicitide required overcoming significant chemical hurdles because small molecules traditionally struggle to influence the interactions between PCSK9 and LDL proteins, according to David Thaisrivongs. Merck’s development team pursued a macrocyclic peptide capable of oral delivery while remaining large enough to interact directly between PCSK9 and the LDL receptor. The discovery process spanned a decade and relied on introducing molecular complexity, which created a major manufacturing challenge regarding commercial viability.
Key milestones in the development included phase 1 studies demonstrating that the molecule could be absorbed orally, as well as medicinal chemistry findings utilizing crystal structure data to enhance potency and stability through chemical cross-links. To streamline production, the team engineered a biocatalytic synthesis employing 13 different enzymes, allowing simultaneous reactions without traditional protection and deprotection steps, according to Thaisrivongs.
Clinical Utility and Administration Requirements for Patients
Because enlicitide is a peptide, patients must take the medication on an empty stomach and wait 30 minutes before eating or drinking to ensure proper absorption and survival through the stomach environment, according to preventative cardiologist Michael Shapiro of Wake Forest University. Shapiro notes that fasting requirements are common for numerous established drugs and should not pose a significant barrier to patient adherence.
Injectable PCSK9 options such as Regeneron’s Praluent, containing alirocumab, and Amgen’s Repatha, containing evolocumab, have been available on the market since 2015. In contrast, an oral pill format like enlicitide may increase accessibility by allowing general practitioners to prescribe the therapy more readily to patients requiring additional LDL-C reduction, according to Shapiro.
Did you know? Enlicitide’s manufacturing process relies on a biocatalytic synthesis involving 13 engineered enzymes to produce the macrocyclic peptide efficiently without standard cross-reactivity protection steps.
Future Outlook and Cost Considerations in Cardiovascular Care
While new therapeutic options expand treatment avenues, cost remains a primary factor influencing broad adoption until generic versions become available, according to Michael Shapiro. Beyond individual prescriptions, long-term advancements in cardiovascular health depend on shifting toward broader preventive measures, logistics, and addressing patient adherence challenges, notes Shapiro.
Frequently Asked Questions
What is Lipfendra (enlicitide)?
Lipfendra is an oral macrocyclic peptide and the first oral PCSK9 inhibitor approved by the FDA to reduce low-density lipoprotein cholesterol in patients needing alternatives to statins.
How does enlicitide differ from existing PCSK9 inhibitors?
Existing PCSK9 inhibitors such as Repatha and Praluent are administered via injection, whereas enlicitide is delivered as an oral pill.
Are there special instructions for taking enlicitide?
Patients must take the medication on an empty stomach and refrain from eating or drinking for 30 minutes afterward to ensure full effectiveness, according to Dr. Michael Shapiro.
When were injectable PCSK9 inhibitors introduced?
Injectable PCSK9 inhibitors have been available on the market since 2015.
Stay informed on the latest pharmaceutical approvals and cardiovascular research. Subscribe to our newsletter or explore our archives for more in-depth reporting.
Keep reading